Neuropsychiatric symptoms related to cholinergic deficits in Parkinson’s disease

Abstract: Given its ability to explain the most frequent motor symptoms of Parkinson’s disease (PD), degeneration of dopaminergic neurons has been considered one of the disease´s main pathophysiological features. Several studies have shown that neurodegeneration also affects noradrenergic, serotonin...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Pérez Lloret, Santiago, Peralta, María Cecilia, Barrantes, Francisco José
Formato: Parte de libro
Lenguaje:Inglés
Publicado: Springer Nature 2020
Materias:
Acceso en línea:https://repositorio.uca.edu.ar/handle/123456789/9542
Aporte de:
id I33-R139123456789-9542
record_format dspace
institution Universidad Católica Argentina
institution_str I-33
repository_str R-139
collection Repositorio Institucional de la Universidad Católica Argentina (UCA)
language Inglés
topic ENFERMEDAD DE PARKINSON
NEUROTRANSMISORES
ENFERMEDADES NEUROGENERATIVAS
TRATAMIENTO MEDICO
spellingShingle ENFERMEDAD DE PARKINSON
NEUROTRANSMISORES
ENFERMEDADES NEUROGENERATIVAS
TRATAMIENTO MEDICO
Pérez Lloret, Santiago
Peralta, María Cecilia
Barrantes, Francisco José
Neuropsychiatric symptoms related to cholinergic deficits in Parkinson’s disease
topic_facet ENFERMEDAD DE PARKINSON
NEUROTRANSMISORES
ENFERMEDADES NEUROGENERATIVAS
TRATAMIENTO MEDICO
description Abstract: Given its ability to explain the most frequent motor symptoms of Parkinson’s disease (PD), degeneration of dopaminergic neurons has been considered one of the disease´s main pathophysiological features. Several studies have shown that neurodegeneration also affects noradrenergic, serotoninergic, cholinergic and other monoaminergic neuronal populations. In this work, the characteristic contribution of cholinergic deficits to cognitive dysfunction, psychosis and sleep disturbances in PD and their treatment will be explored. Important neurophysiological processes at the root of several motor and cognitive functions remit to cholinergic neurotransmission at the synaptic pathway and circuital levels. The bulk of evidence highlights the link between cholinergic alterations and the aforementioned symptoms. The pathophysiology of these symptoms is related to degeneration of cholinergic nuclei, most importantly the nucleus basalis magnocellularis and the pedunculo-pontine nucleus. Rivastigmine, a drug that increases cholinergic tone by inhibiting the enzyme cholinesterase, is effective for dementia, whereas the use of Donepezil is still in the realm of investigation. Evidence on the clinical effects of these drugs for psychosis and REM-sleep disturbances is still weak. Anticholinergic drugs should be used with caution in PD, as they may aggravate these cholinergic symptoms.
format Parte de libro
author Pérez Lloret, Santiago
Peralta, María Cecilia
Barrantes, Francisco José
author_facet Pérez Lloret, Santiago
Peralta, María Cecilia
Barrantes, Francisco José
author_sort Pérez Lloret, Santiago
title Neuropsychiatric symptoms related to cholinergic deficits in Parkinson’s disease
title_short Neuropsychiatric symptoms related to cholinergic deficits in Parkinson’s disease
title_full Neuropsychiatric symptoms related to cholinergic deficits in Parkinson’s disease
title_fullStr Neuropsychiatric symptoms related to cholinergic deficits in Parkinson’s disease
title_full_unstemmed Neuropsychiatric symptoms related to cholinergic deficits in Parkinson’s disease
title_sort neuropsychiatric symptoms related to cholinergic deficits in parkinson’s disease
publisher Springer Nature
publishDate 2020
url https://repositorio.uca.edu.ar/handle/123456789/9542
work_keys_str_mv AT perezlloretsantiago neuropsychiatricsymptomsrelatedtocholinergicdeficitsinparkinsonsdisease
AT peraltamariacecilia neuropsychiatricsymptomsrelatedtocholinergicdeficitsinparkinsonsdisease
AT barrantesfranciscojose neuropsychiatricsymptomsrelatedtocholinergicdeficitsinparkinsonsdisease
bdutipo_str Repositorios
_version_ 1764820528233709569